Completed PHASE1 INTERVENTIONAL 6-arm NCT02737605

A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants

A Randomized, Double-Blind (Periods 1 to 3), Placebo- and Positive-Controlled, Single Dose, 4-Period, Crossover Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Subjects

Sponsor: Janssen Research & Development, LLC

Conditions Healthy

Interventions Intranasal Esketamine Intranasal Placebo Intravenous Esketamine Intravenous Placebo Moxifloxacin Oral Placebo

Updated 7 times since 2017 Last updated: Apr 10, 2018 Started: Jul 1, 2016 Primary completion: Feb 23, 2017 Completion: Feb 23, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Janssen Research & Development, LLC leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2018 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Apr 2017 — May 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jan 2017 — Apr 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany